LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

NVO

112.01

-0.39%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

Kodu・Aktsiate loetelu・Alkermes PLC

Alkermes PLC

Suletud

Sektor Tervishoid

26.44 -0.19

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

26.26

Max

26.76

Põhinäitajad
By Trading Economics
Sissetulek	55M 91M
Müük	49M 399M
P/E Sektori keskmine	7.17 112.16
Aktsiakasum	0.72
Kasumimarginaal	22.891
EBITDA	68M 129M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+31.55 upside

Turustatistika
By TradingEconomics
Turukapital	-139M 4.7B
Eelmine avamishind	26.63
Eelmine sulgemishind	26.44

Uudiste sentiment

By Acuity

50%

181 / 389 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

26.01 / 28.09 Toetus ja vastupanu

Alkermes PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. dets 2023, 11:06 UTC

Omandamised, ülevõtmised, äriostud

Alkermes Athlone Facility Has About 400 Employees >ALKS

14. dets 2023, 11:06 UTC

Omandamised, ülevõtmised, äriostud

Alkermes to Get Cash Payment of $92.5 Million for Facility, Related Assets >ALKS

Võrdlus sarnastega

Hinnamuutus

Alkermes PLC Prognoos

Hinnasiht

By TipRanks

31.55% tõus

12 kuu keskmine prognoos

Keskmine 34.9 USD 31.55%

Kõrge 50 USD

Madal 25 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Alkermes PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Alkermes PLC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

26.01 / 28.09Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

181 / 389 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.